Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
An, Ho Jung
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
NANORAY-312, NCT04892173 / 2021-002163-22: NBTXR3 With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Canada, Japan, US, RoW	NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy	Nanobiotix, Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients	Recruiting	2	60	US, RoW	MIT-001 plus CCRT	MitoImmune Therapeutics	Head and Neck Squamous Cell Carcinoma, Oral Mucositis	04/24	12/24